Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations

References

• RowleyJDLetter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa stainingNature197324354052902934126434
   PubMed Web of Science ®Google Scholar
• American Cancer SocietyCancer Facts & Figures 2013 Available from: http://www.cancer.org/research/cancerfactsstatistics/cancerfacts-figures2013/indexAccessed May 20, 2014
   Google Scholar
• HuangXCortesJKantarjianHEstimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapyCancer2012118123123312722294282
   PubMed Web of Science ®Google Scholar
• O’BrienSGGuilhotFLarsonRAImatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med200334811994100412637609
   PubMed Web of Science ®Google Scholar
• DrukerBJGuilhotFO’BrienSGFive-year follow-up of patients receiving imatinib for chronic myeloid leukemiaN Engl J Med2006355232408241717151364
   PubMed Web of Science ®Google Scholar
• ShahNPGuilhotFCortesJELong-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of phase 3 studyBlood2014123152317232424569263
   PubMed Web of Science ®Google Scholar
• KantarjianHMGilesFJBhallaKNNilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up resultsBlood201111741141114521098399
   PubMed Web of Science ®Google Scholar
• SaglioGHochhausAHughesTPENESTnd update: nilotinib (NIL) vs imatinib (IM) in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and Sokal risk at diagnosis on long-term outcomesBlood20131222192
   Web of Science ®Google Scholar
• HochhausAKimDWShahNPFour-year follow-up of patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib or imatinib: efficacy based on early responseBlood201312221653
   Web of Science ®Google Scholar
• KhouryHJCortesJEKantarjianHMBosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failureBlood2012119153403341222371878
   PubMed Web of Science ®Google Scholar
• CortesJEKantarjianHMBrummendorfTHSafety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinibBlood2011118174567457621865346
   PubMed Web of Science ®Google Scholar
• Remsing RixLLRixUColingeJGlobal target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cellsLeukemia200923347748519039322
   PubMed Web of Science ®Google Scholar
• CortesJEKantarjianHShahNPPonatinib in refractory Philadelphia chromosome–positive leukemiasN Engl J Med2012367222075208823190221
   PubMed Web of Science ®Google Scholar
• CortesJEKimDWPinilla-IbarzJA Phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemiasN Engl J Med2013369191783179624180494
   PubMed Web of Science ®Google Scholar
• KhanAMBixbyDLBCR-ABL inhibitors: updates in the management of patients with chronic-phase chronic myeloid leukemiaHematology Epub2013122
   Google Scholar
• JabbourEBranfordSSaglioGJonesDCortesJEKantarjianHMPractical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemiaCancer201111791800181121509757
   PubMed Web of Science ®Google Scholar
• JabbourEJonesDKantarjianHMLong-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutationsBlood2009114102037204319567878
   PubMed Web of Science ®Google Scholar
• ErnstTHochhausAChronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progressionSemin Oncol2012391586622289492
   PubMed Web of Science ®Google Scholar
• BaccaraniMCastagnettiFGugliottaGPalandriFRostiGTreatment recommendations for Chronic Myeloid LeukemiaMediterr J Hematol Infect Dis201461e201400524455114
   PubMedGoogle Scholar
• National Comprehensive Cancer NetworkChronic Myelogenous Leukemia version 32014 Available from: http://www.nccn.org/about/news/ebulletin/ebulletindetail.aspx?ebulletinid=277Accessed May 21, 2014
   Google Scholar
• RadichJPMonitoring response to tyrosine kinase inhibitor therapy, mutational analysis, and new treatment options in chronic myelogenous leukemiaJ Natl Compr Canc Netw2013115 Suppl66366623704238
   PubMed Web of Science ®Google Scholar
• MullerMCCortesJEKimDWDasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutationsBlood2009114244944495319779040
   PubMed Web of Science ®Google Scholar
• CangSLiuDP-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemiaJ Hematol Oncol200811518828913
   PubMed Web of Science ®Google Scholar
• HughesTSaglioGBranfordSImpact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phaseJ Clin Oncol200927254204421019652056
   PubMed Web of Science ®Google Scholar
• RusconiFPiazzaRVaggeEGambacorti-PasseriniCBosutinib: a review of preclinical and clinical studies in chronic myelogenous leukemiaExpert Opin Pharmacother201415570171024479382
   PubMed Web of Science ®Google Scholar
• Bethelmie-BryanBLordKHollowaySKhouryHJBosutinib treatment for Philadelphia chromosome-positive leukemiasFuture Oncol201410217918524490604
   PubMed Web of Science ®Google Scholar
• DalzellMDPonatinib pulled off market over safety issuesManage Care201322124243
   Google Scholar
• [No authors listed]In brief: ponatinib (Inclusig) returnsMed Lett Drugs Ther2014561434824457561
   PubMedGoogle Scholar
• AlvandiFKwitkowskiVEKoCWUS Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemiaOncologist2014191949924309980
   PubMed Web of Science ®Google Scholar
• CortesJLiptonJHReaDPhase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutationBlood2012120132573258022896000
   PubMed Web of Science ®Google Scholar
• AmsbergGKKoschmiederSProfile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemiaOnco Targets Ther201369910623493838
   PubMed Web of Science ®Google Scholar
• LevinsonNMBoxerSGA conserved water-mediated hydrogen bond network defines bosutinib’s kinase selectivityNat Chem Biol201410212713224292070
   PubMed Web of Science ®Google Scholar
• SummyJMGallickGESrc family kinases in tumor progression and metastasisCancer Metastasis Rev200322433735812884910
   PubMed Web of Science ®Google Scholar
• JohnsonFMGallickGESRC family nonreceptor tyrosine kinases as molecular targets for cancer therapyAnticancer Agents Med Chem20077665165918045060
   PubMed Web of Science ®Google Scholar
• LiSSrc-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemiaLeuk Lymphoma2008491192618203007
   PubMed Web of Science ®Google Scholar
• StansfieldLHughesTEWalsh-ChocolaadTLBosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemiaAnn Pharmacother201347121703171124396109
   PubMed Web of Science ®Google Scholar
• SyedYYMcCormackPLPloskerGLBosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemiaBioDrugs201428110712024420842
   PubMed Web of Science ®Google Scholar
• AbbasRHugBALeisterCGaaloulMEChalonSSonnichsenDA phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjectsCancer Chemother Pharmacol201269122122721691746
   PubMed Web of Science ®Google Scholar
• RassiFEKhouryHJBosutinib: a SRC-ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemiaPharmgenomics Pers Med20136576224019749
   PubMedGoogle Scholar
• TomiloDLSmithPFOgundeleABInhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteersPharmacotherapy200626334134616503713
   PubMed Web of Science ®Google Scholar
• PfizerBosulib. Prescribing information Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=884Accessed May 21, 2014
   Google Scholar
• HsyuPHMouldDRUptonRNAmanteaMPharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemiaCancer Chemother Pharmacol201371120921823070145
   PubMed Web of Science ®Google Scholar
• Gambacorti-PasseriniCCortesJEKhouryHJSafety and efficacy of bosutinib in patients with AP and BP CML and ph+ ALL following resistance/intolerance to imatinib and other TKIs: Update from study SKI-200ASCO Meeting Abstracts20102815 Suppl6509
   Google Scholar
• RedaelliSPiazzaRRostagnoRActivity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutantsJ Clin Oncol200927346947119075254
   PubMed Web of Science ®Google Scholar
• CortesJEKimDWKantarjianHMBosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trialJ Clin Oncol201230283486349222949154
   PubMed Web of Science ®Google Scholar
• ShenAQWilsonNMGleasonSLKhouryHJBosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overviewTher Adv Hematol201451131724490020
   PubMedGoogle Scholar
• KantarjianHShahNPHochhausADasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemiaN Engl J Med2010362242260227020525995
   PubMed Web of Science ®Google Scholar
• SaglioGKimDWIssaragrisilSNilotinib versus imatinib for newly diagnosed chronic myeloid leukemiaN Engl J Med2010362242251225920525993
   PubMed Web of Science ®Google Scholar
• PhillipsKMPinilla-IbarzJSotomayorEQuality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparisonSupport Care Cancer20132141097110323179489
   PubMed Web of Science ®Google Scholar
• Pinilla-IbarzJCortesJMauroMJIntolerance to tyrosine kinase inhibitors in chronic myeloid leukemiaCancer2011117468869720922786
   PubMed Web of Science ®Google Scholar
• TraskPCCellaDBessonNKellyVMassziTKimDWHealth-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemiaLeuk Res201236443844222036634
   PubMed Web of Science ®Google Scholar
• Gambacorti-PasseriniCAntoliniLMahonFXMulticenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinibJ Natl Cancer Inst2011103755356121422402
   PubMedGoogle Scholar